ClearPoint Neuro (NASDAQ:CLPT) Given New $25.00 Price Target at Stifel Nicolaus

ClearPoint Neuro (NASDAQ:CLPT) had its target price increased by Stifel Nicolaus from $19.00 to $25.00 in a report published on Tuesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other brokerages have also issued reports on CLPT. Lake Street Capital upped their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, January 21st. B. Riley increased their price objective on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th.

ClearPoint Neuro Stock Up 10.1 %

ClearPoint Neuro stock opened at $13.09 on Tuesday. The company has a fifty day simple moving average of $15.56 and a 200-day simple moving average of $14.05. The firm has a market capitalization of $361.70 million, a price-to-earnings ratio of -18.97 and a beta of 1.06. ClearPoint Neuro has a 52-week low of $5.11 and a 52-week high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The company had revenue of $7.77 million during the quarter, compared to analyst estimates of $8.23 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. On average, research analysts anticipate that ClearPoint Neuro will post -0.66 EPS for the current fiscal year.

Institutional Trading of ClearPoint Neuro

Institutional investors and hedge funds have recently bought and sold shares of the business. Jefferies Financial Group Inc. acquired a new position in shares of ClearPoint Neuro in the fourth quarter valued at approximately $265,000. Two Sigma Investments LP purchased a new position in ClearPoint Neuro in the 4th quarter valued at approximately $159,000. State of Wyoming acquired a new position in shares of ClearPoint Neuro in the fourth quarter worth $145,000. Man Group plc purchased a new stake in shares of ClearPoint Neuro during the fourth quarter worth $1,107,000. Finally, Occudo Quantitative Strategies LP purchased a new stake in shares of ClearPoint Neuro during the fourth quarter worth $155,000. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.